Literature DB >> 28877026

Effectiveness of a Third Dose of MMR Vaccine for Mumps Outbreak Control.

Cristina V Cardemil1, Rebecca M Dahl1, Lisa James1, Kathleen Wannemuehler1, Howard E Gary1, Minesh Shah1, Mona Marin1, Jacob Riley1, Daniel R Feikin1, Manisha Patel1, Patricia Quinlisk1.   

Abstract

BACKGROUND: The effect of a third dose of the measles-mumps-rubella (MMR) vaccine in stemming a mumps outbreak is unknown. During an outbreak among vaccinated students at the University of Iowa, health officials implemented a widespread MMR vaccine campaign. We evaluated the effectiveness of a third dose for outbreak control and assessed for waning immunity.
METHODS: Of 20,496 university students who were enrolled during the 2015-2016 academic year, mumps was diagnosed in 259 students. We used Fisher's exact test to compare unadjusted attack rates according to dose status and years since receipt of the second MMR vaccine dose. We used multivariable time-dependent Cox regression models to evaluate vaccine effectiveness, according to dose status (three vs. two doses and two vs. no doses) after adjustment for the number of years since the second dose.
RESULTS: Before the outbreak, 98.1% of the students had received at least two doses of MMR vaccine. During the outbreak, 4783 received a third dose. The attack rate was lower among the students who had received three doses than among those who had received two doses (6.7 vs. 14.5 cases per 1000 population, P<0.001). Students had more than nine times the risk of mumps if they had received the second MMR dose 13 years or more before the outbreak. At 28 days after vaccination, receipt of the third vaccine dose was associated with a 78.1% lower risk of mumps than receipt of a second dose (adjusted hazard ratio, 0.22; 95% confidence interval, 0.12 to 0.39). The vaccine effectiveness of two doses versus no doses was lower among students with more distant receipt of the second vaccine dose.
CONCLUSIONS: Students who had received a third dose of MMR vaccine had a lower risk of mumps than did those who had received two doses, after adjustment for the number of years since the second dose. Students who had received a second dose of MMR vaccine 13 years or more before the outbreak had an increased risk of mumps. These findings suggest that the campaign to administer a third dose of MMR vaccine improved mumps outbreak control and that waning immunity probably contributed to propagation of the outbreak. (Funded by the Centers for Disease Control and Prevention.).

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28877026      PMCID: PMC6546095          DOI: 10.1056/NEJMoa1703309

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  24 in total

1.  The effectiveness of the mumps component of the MMR vaccine: a case control study.

Authors:  Richard Harling; Joanne M White; Mary E Ramsay; Karen F Macsween; Corry van den Bosch
Journal:  Vaccine       Date:  2005-07-01       Impact factor: 3.641

2.  Mumps vaccination coverage and vaccine effectiveness in a large outbreak among college students--Iowa, 2006.

Authors:  Mona Marin; Patricia Quinlisk; Tom Shimabukuro; Charu Sawhney; Cedric Brown; Charles W Lebaron
Journal:  Vaccine       Date:  2008-05-19       Impact factor: 3.641

3.  Mumps outbreaks in vaccinated populations: are available mumps vaccines effective enough to prevent outbreaks?

Authors:  Gustavo H Dayan; Steven Rubin
Journal:  Clin Infect Dis       Date:  2008-12-01       Impact factor: 9.079

Review 4.  Mumps resurgences in the United States: A historical perspective on unexpected elements.

Authors:  Albert E Barskey; John W Glasser; Charles W LeBaron
Journal:  Vaccine       Date:  2009-10-19       Impact factor: 3.641

5.  Vaccine effectiveness estimates, 2004-2005 mumps outbreak, England.

Authors:  Cheryl Cohen; Joanne M White; Emma J Savage; Judith R Glynn; Yoon Choi; Nick Andrews; David Brown; Mary E Ramsay
Journal:  Emerg Infect Dis       Date:  2007-01       Impact factor: 6.883

6.  Mumps vaccine performance among university students during a mumps outbreak.

Authors:  Margaret M Cortese; Hannah T Jordan; Aaron T Curns; Patricia A Quinlan; Kim A Ens; Patricia M Denning; Gustavo H Dayan
Journal:  Clin Infect Dis       Date:  2008-04-15       Impact factor: 9.079

7.  Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up.

Authors:  Irja Davidkin; Sari Jokinen; Mia Broman; Pauli Leinikki; Heikki Peltola
Journal:  J Infect Dis       Date:  2008-04-01       Impact factor: 5.226

8.  Effectiveness of previous mumps vaccination during a summer camp outbreak.

Authors:  Joshua K Schaffzin; Lynn Pollock; Cynthia Schulte; Kyle Henry; Gustavo Dayan; Debra Blog; Perry Smith
Journal:  Pediatrics       Date:  2007-10       Impact factor: 7.124

9.  Persistence of mumps antibodies after 2 doses of measles-mumps-rubella vaccine.

Authors:  Charles W LeBaron; Bagher Forghani; Carol Beck; Cedric Brown; Daoling Bi; Cynthia Cossen; Bradley J Sullivan
Journal:  J Infect Dis       Date:  2009-02-15       Impact factor: 5.226

10.  Long-term persistence of mumps antibody after receipt of 2 measles-mumps-rubella (MMR) vaccinations and antibody response after a third MMR vaccination among a university population.

Authors:  Anand A Date; Moe H Kyaw; Alison M Rue; Julie Klahn; Leann Obrecht; Terry Krohn; Josh Rowland; Steve Rubin; Thomas J Safranek; William J Bellini; Gustavo H Dayan
Journal:  J Infect Dis       Date:  2008-06-15       Impact factor: 7.759

View more
  46 in total

1.  Outbreak of mumps in a student population with high vaccination coverage in China: time for two-dose vaccination.

Authors:  Wei Qin; Yao Wang; Tao Yang; Xiao-Kang Xu; Xiang-Mei Meng; Chang-Jun Zhao; Shao-Yi Li; Shao-Yu Xie; Kai-Chun Li; Hong Su
Journal:  Hum Vaccin Immunother       Date:  2019-03-15       Impact factor: 3.452

Review 2.  Mumps: an Update on Outbreaks, Vaccine Efficacy, and Genomic Diversity.

Authors:  Eugene Lam; Jennifer B Rosen; Jane R Zucker
Journal:  Clin Microbiol Rev       Date:  2020-02-26       Impact factor: 26.132

3.  Waxing Understanding of Waning Immunity.

Authors:  Benjamin A Lopman; Virginia E Pitzer
Journal:  J Infect Dis       Date:  2018-03-05       Impact factor: 5.226

4.  Close the gap for routine mumps vaccination in Japan.

Authors:  Taito Kitano
Journal:  Hum Vaccin Immunother       Date:  2020-06-12       Impact factor: 3.452

5.  Pre-vaccination IgG screening for mumps is the most cost-effectiveness immunization strategy among Health Care Workers.

Authors:  Luca Coppeta; Ottavia Balbi; Savino Baldi; Antonio Pietroiusti; Andrea Magrini
Journal:  Hum Vaccin Immunother       Date:  2019-03-27       Impact factor: 3.452

6.  Monitoring Viral Genetic Variation as a Tool To Improve Molecular Diagnostics for Mumps Virus.

Authors:  Meik Dilcher; Kevin Barratt; Jennifer Douglas; Andrew Strathdee; Trevor Anderson; Anja Werno
Journal:  J Clin Microbiol       Date:  2018-09-25       Impact factor: 5.948

7.  Differential durability of immune responses to measles and mumps following MMR vaccination.

Authors:  Richard B Kennedy; Inna G Ovsyannikova; Antonia Thomas; Beth R Larrabee; Steven Rubin; Gregory A Poland
Journal:  Vaccine       Date:  2019-02-20       Impact factor: 3.641

8.  Vaccine waning and mumps re-emergence in the United States.

Authors:  Joseph A Lewnard; Yonatan H Grad
Journal:  Sci Transl Med       Date:  2018-03-21       Impact factor: 17.956

9.  Genomic characterization of mumps viruses from a large-scale mumps outbreak in Arkansas, 2016.

Authors:  Duah Alkam; Piroon Jenjaroenpun; Thidathip Wongsurawat; Zulema Udaondo; Preecha Patumcharoenpol; Michael Robeson; Dirk Haselow; William Mason; Intawat Nookaew; David Ussery; Se-Ran Jun
Journal:  Infect Genet Evol       Date:  2019-07-15       Impact factor: 3.342

10.  Mumps Outbreak in a Highly Vaccinated University-Affiliated Setting Before and After a Measles-Mumps-Rubella Vaccination Campaign-Iowa, July 2015-May 2016.

Authors:  Minesh Shah; Patricia Quinlisk; Andrew Weigel; Jacob Riley; Lisa James; James Patterson; Carole Hickman; Paul A Rota; Rebekah Stewart; Nakia Clemmons; Nicholas Kalas; Cristina Cardemil
Journal:  Clin Infect Dis       Date:  2018-01-06       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.